Statin Use Speeds Onset of Coronary Adverse Event Hospitalizations

A new study of 3,516 Italian patients¹ prescribed statins for high cholesterol looked into the issue of how well the therapy lowered cholesterol and the effect of therapy on the time to first hospitalization for a coronary event.

Not surprisingly, using statins to take a sledgehammer to the body’s natural system of cholesterol production did indeed lower the cholesterol level, especially in those patients who were very compliant to taking the drug. 

Not surprisingly to me (but surprising to the pill pushing doctors), those taking the statins most consistently also ended up in the hospital with a coronary event sooner than the other patients – despite lower cholesterol.

Of course, this study was Italian.  No American University will dare publish adverse statin Class of drugs aka HMG-CoA reductase inhibitors, that are used to lower cholesterol levels by inhibiting the HMG-CoA reductase enzyme that plays a central role in liver function and cholesterol production. findings – for fear of losing funding for future studies from Big Pharma.  Only the most slanted and tainted data is presented – propping up a 20-billion-a-year scam that is paid for by “we the people.” 

I’ll guarantee you that you won’t see this study in any national headlines and doctors around the world will actively ignore it.

As I pointed out last December, the dramatic rise in heart failure rates in the U.S. is timeline associated with the dramatic increase in the use of statins - a scandal waiting to blow its lid.